Eli Lilly breaks ground on USD 5 billion plant. Eli Lilly stock falls 1.30 percent
Published on 10/23/2026 at 11:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCapacity and earnings calendar
- Eli Lilly broke ground on a USD 5.00 billion Virginia facility on October 22, 2026.
- Second-quarter 2026 revenue reached USD 22.97 billion, up 47.70 percent year over year.
- Eli Lilly stock trades at EUR 1,159.30 at 11:35 a.m. CEST at Lang & Schwarz on October 23, 2026, 1.30 percent below the Xetra close of October 22, 2026.
Eli Lilly and Company (ISIN US5324571083) broke ground on a USD 5.00 billion Virginia manufacturing facility, while its stock was trading at EUR 1,159.30 at Lang & Schwarz on October 23, 2026, at 11:35 a.m. CEST, down 1.30 percent versus the Xetra close of October 22, 2026 (EUR 1,174.60). The facility story was reported by MarketBeat on October 22, 2026.
Capacity becomes the central question
The Virginia project is part of more than USD 50.00 billion in planned US production expansion, according to MarketBeat. The site is expected to create 650 jobs and combine active pharmaceutical ingredient production with finished medicines, giving Lilly a direct way to expand supply capacity.
The investment arrives before the next earnings test. MarketBeat reported on October 20, 2026, that Goldman Sachs raised its price target from USD 1,371.00 to USD 1,413.00 and reiterated a Buy rating. The target is 21.90 percent above the Lang & Schwarz price when calculated across different currencies, so no direct target-distance comparison is used here.
What does the latest quarter show?
In the second quarter of 2026, revenue reached USD 22.97 billion, up 47.70 percent from the second quarter of 2025, while net income was USD 7.10 billion. The earnings data were reported by EarningsMadness from the company filing. The revenue increase gives the capacity buildout a concrete commercial backdrop, although pricing and competition remain important variables.
Three dated developments
On September 30, 2026, Lilly reported that its EloraTZP combination therapy produced weight loss of up to 23.30 percent in a Phase 2b trial, according to Yahoo Finance. On October 15, 2026, Lilly confirmed October 29, 2026, for its third-quarter results announcement and earnings call. On October 22, 2026, the company broke ground on the USD 5.00 billion Virginia facility, according to MarketBeat.
When are the next key dates?
Lilly's next reported date is October 29, 2026, for third-quarter results before the US market opens. The company's investor-relations page also lists Lilly Innovation Day for December 7, 2026, from 9:00 a.m. to 1:00 p.m. EST.
Stock stays below the prior close
The euro quotation leaves the stock 1.30 percent below the EUR 1,174.60 Xetra close of October 22, 2026. The primary listing is on the NYSE, where the finance quote showed USD 1,306.69 in pre-market trading on October 23, 2026 at 5:13 a.m. EDT.
The further course of trading is shown by the continuously updated real-time quote of Eli Lilly and Co stock.
Eli Lilly and Company stock facts
- Company: Eli Lilly and Company
- ISIN: US5324571083
- Ticker: LLY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 23, 2026, 11:35 a.m. CEST): EUR 1,159.30
- Change versus Xetra close: minus 1.30 percent
- Xetra close (October 22, 2026): EUR 1,174.60
- Market capitalization: USD 1.2 trillion (as of October 23, 2026)
- 52-week range: USD 806.02-1,321.21 (as of October 23, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: S&P 500
- Next earnings date: October 29, 2026
Market context: Market report S&P 500.
